Independent batch analysis
Batch Verification
Passed all tests
99.68%
Batch average by RP-HPLC
10.05 mg
Batch average across three vials
Confirmed
Compound identity result
No growth
Reported sterility result
0.12 EU/mL
LAL test result
Results are specific to batch GLP-TRZ3427 and should not be generalized to any other lot. Review the complete certificate for full methods and results.
Product overview
Tirzepatide 10 mg Research Material
Tirzepatide is described in peer-reviewed scientific literature as a synthetic peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-receptor profile is the basis for its study in metabolic and receptor-signalling research.
GLP-2 TRZ is Peptora’s catalogue designation for this tirzepatide research material. It is supplied as lyophilized powder with a labelled quantity of 10 mg per vial.
Published studies listed below are provided strictly as scientific background. They do not establish that Peptora’s material is suitable for clinical use, and they are not instructions or recommendations for human or veterinary use.
Research Context at a Glance
Published scientific literature describes tirzepatide through a dual-receptor research model:
GIP receptor
GLP-1 receptor
This summary describes the investigational mechanism reported in scientific literature. It is not a statement of intended use for this laboratory material.
Batch documentation
Traceable From Product to Certificate
The product, batch identifier and Elementrix report are presented together so researchers can review the applicable certificate before ordering.
- ✓ Batch-specific COA available online
- ✓ Direct Elementrix verification link
- ✓ Reported purity, identity and net content
Expanded third-party review
More Than a Purity Percentage
This batch certificate reports identity, net content, sterility and endotoxin in addition to purity—giving researchers a broader documented testing profile than a purity-only report.
The Peptora testing difference
We Test Beyond Purity
A purity percentage is only one part of a meaningful batch review. Peptora commissioned an expanded third-party panel so researchers can examine identity, content and selected quality indicators – all tied to one independently verifiable batch certificate.
✓ Net content
✓ LC-MS identity
✓ Sterility
✓ Endotoxin
One batch-specific Elementrix certificate with direct verification.
What the expanded panel covers
Purity and content
RP-HPLC purity and average net content are reported for the batch, including individual results from three sampled vials.
Identity confirmation
LC-MS analysis is reported as confirming the identity of the material evaluated by Elementrix.
Sterility and endotoxin
The certificate reports no growth for sterility and an endotoxin result of 0.12 EU/mL.
Direct verification
The report number can be checked through Elementrix so the published certificate is not dependent on Peptora’s description alone.
Product care and fulfilment
Storage and Shipping
Storage
Store the lyophilized vial at -20°C and protect it from light, as specified on the batch certificate.
Do not use the vial if its packaging or integrity appears compromised.
Ships from Ontario
Orders are fulfilled from Ontario, Canada. Review Peptora’s shipping information for current processing, delivery and order-handling details.
Documentation built in
Why Choose Peptora?
Peptora Peptide Labs is structured around transparent, batch-specific documentation for Canadian laboratory researchers.
Independent analysis
Testing results are documented through a third-party Elementrix certificate rather than an internal specification sheet alone.
Batch-specific COAs
The displayed certificate is tied to a defined report number and batch identifier for straightforward traceability.
Direct verification
Researchers can open the complete PDF and follow the independent verification link from the product page.
Canadian fulfilment
This research material ships from Ontario, Canada.
Clear intended use
Product presentation and documentation clearly identify the material as intended only for laboratory research.
Accessible documentation
Testing standards, certificates and product information are organized for review before ordering.
Product questions
Frequently Asked Questions
Clear answers about this Tirzepatide 10 mg research material, its batch documentation, independent testing and intended use.
Important product restriction
For Laboratory Research Use Only
All Peptora Peptide Labs products are intended solely for controlled laboratory research. This material is not for human or veterinary consumption and is not intended for compounding, clinical use, diagnosis, treatment, cure or prevention of disease.
Peptora does not provide medical advice, dosing instructions, administration guidance or treatment recommendations.
Scientific background references
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). The Lancet. 2021.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist. Cardiovascular Diabetology. 2022.
References are provided for scientific background only. Published clinical research does not validate this specific Peptora batch or authorize use of this product in humans or animals.
